Journal
Blood Advances
Publication Date
9-26-2023
Volume
7
Issue
18
First Page
5272
Last Page
5280
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023010254
Rights and Permissions
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Lisano J, Wen R, Akyol A, Moskowitz AJ. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv. 2023 Sep 26;7(18):5272-5280. doi: 10.1182/bloodadvances.2023010254. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Zinzani, Pier Luigi; Santoro, Armando; Gritti, Giuseppe; Brice, Pauline; Barr, Paul M; Kuruvilla, John; Cunningham, David; Kline, Justin; Johnson, Nathalie A; Mehta-Shah, Neha; Lisano, Julie; Wen, Rachael; Akyol, Alev; and Moskowitz, Alison J, "Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up." Blood Advances. 7, 18. 5272 - 5280. (2023).
https://digitalcommons.wustl.edu/oa_4/2312
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
